Stuck in the middle. The highly anticipated drug-eluting stents are good for heart patients, but are they bad for hospital balance sheets?
The Food and Drug Administration stands ready to OK a highly anticipated drug-eluting stent as early as this week, but revenue at hospitals may fall as a result of declining volumes in cardiovascular surgeries, a lucrative service. The problem comes "because hospitals are stuck in the middle," says Jeffery Morneault (left), an executive at Health Alliance of Greater Cincinnati.